Skip to content

Clinical trials

Diabetes Mellitus, Type 2 trials in the Netherlands with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Diabetes Mellitus, Type 2 Phase: Not applicable Country / region: Netherlands Clear all

97 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20021
20071
20082
20093
20105
201111
20127
20135
20147
20154
20166
20173
20184
20196
20201
20216
20227
20234
20246
20253
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed70
Unknown status16
Recruiting5
Not yet recruiting3
Active, not recruiting1
Suspended1
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Maastricht University Medical Center32
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)9
Maastricht University8
Radboud University Medical Center7
Amsterdam UMC, location VUmc5
UMC Utrecht5
Wageningen University4
Fractyl Health Inc.3
Erasmus Medical Center2
Leiden University Medical Center2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes Mellitus, Type 297
Obesity22
Insulin Resistance19
Diabetes Mellitus12
Glucose Intolerance8
Glucose Metabolism Disorders3
Metabolic Diseases3
Overweight3
Cardiovascular Diseases2
Diabetes Mellitus, Type 12

Trials

Showing 1 to 25 of 97. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.